Sorry to keep banging on this idea but i feel like it's worth 1 more mention. DEPO still has some upside potential, imo. A little study i did shows 77% of stocks (10/13) rose, average return was +6% in the final 4 weeks before an FDA new drug decision. That's for stocks greater than 200m mkt cap + selling 1 week before the decision. Worst trade was -11.7%. Best trade, +29%.
For stocks < 200m mkt cap, results were bad -- only 27% gainers (3/11) in the last 4 weeks, average return was -.93% Worst trade was -26%. Best trade, +41%.
I know, pretty small sample sizes and maybe some data snooping here but others swear by the process, i'm 2 for 3 in pharma runup trades and well ... Cheers